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Baﬁlomycin A1Alpha-synuclein aggregation plays a central role in Parkinson's disease pathology. Direct transmission of
alpha-synuclein from pathologically affected to healthy unaffected neurons may be important in the
anatomical spread of the disease through the nervous system.We have demonstrated that exosomes released
from alpha-synuclein over-expressing SH-SY5Y cells contained alpha-synuclein and these exosomes were
capable of efﬁciently transferring alpha-synuclein protein to normal SH-SY5Y cells. Moreover, the incubation
of cells with ammonium chloride or baﬁlomycin A1 to produce the lysosomal dysfunction recently reported in
Parkinson's disease led to an increase in the release of alpha-synuclein in exosomes and a concomitant
increase in alpha-synuclein transmission to recipient cells. This study clearly demonstrates the importance of
exosomes in both the release of alpha synuclein and its transmission between cells and suggests that factors
associated with PD pathology accelerate this process. These mechanisms may play an important role in PD
pathology and provide a suitable target for therapeutic intervention.l Neurosciences, Institute of
Street, London NW3 2PF, UK.
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Parkinson's disease (PD) is a progressive neurodegenerative
disorder characterised pathologically by the loss of dopaminergic
neurons in the substantia nigra pars compacta and the presence of
Lewy bodies (LB) which are intra-cytoplasmic inclusions containing
high levels of alpha-synuclein (Spillantini et al., 1997). The discovery
of mutations (A53T, A30P, E46K) and multiplications of the alpha-
synuclein gene in familial forms of PD further demonstrate the
importance of alpha-synuclein to PD pathology (Lee and Trojanowski
2006). Host-to-graft propagation of alpha-synuclein-positive Lewy-
like pathology has recently been demonstrated in long-term mesen-
cephalic transplants in PD patients (Li et al., 2008; Kordower et al.
2008). In vitro experiments co-culturing over-expressing cells with
non-expressing and neuronal precursor cells also showed cell-to-cell
transmission of alpha-synuclein (Desplats et al., 2009). These studies
support the notion that alpha-synuclein can be directly transmitted
from pathologically affected to healthy unaffected neurons leading toprogression of the disease process through the nervous system. This
could be an explanation of the step-wise progression of the disease
pathology and the involvement of anatomically distinct pathways.
Recently, a study described the secretion of alpha-synuclein in
association with membrane vesicles of composition and biophys-
ical properties consistent with their identiﬁcation as exosomes
(Emmanoulidou et al., 2010).
Exosomes are membrane-bound vesicles of endocytic origin
released by numerous cell types and found in abundance in body
ﬂuids (Simpson et al., 2008) where they act as natural carriers of
mRNA, miRNA and proteins (Schorey and Bhatnagar 2008). Exosomes
have been associated with prion protein release from cultured non-
neuronal and neuronal cells (Fevrier et al., 2004; Vella et al., 2007);
moreover, exosomes released from prion-infected neuronal cells were
efﬁcient initiators of prion propagation in uninfected recipient cells.
We examined exosomes released from SH-SY5Y cells stably over-
expressing WT alpha-synuclein to determine if they contained alpha-
synuclein protein and whether exosomes can mediate alpha-
synuclein transfer between neuronal cells. The inter-cellular transfer
of alpha-synuclein may not in itself be sufﬁcient to propagate PD
pathology and other factors may play a role. Given the observation
that lysosomal function is essential for alpha-synuclein metabolism
and the evidence of lysosomal dysfunction in PD brains (Alvarez-
Erviti et al., 2010) we assessed whether lysosomal dysfunction could
inﬂuence alpha-synuclein release and transmission.
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All reagents were obtained from Sigma Aldrich (Dorset, UK) or
Merck (Nottingham, UK) unless otherwise stated.
Cell cultures
Normal SH-SY5Y cell and a clone constitutively expressing full
length human wild type alpha-synuclein with a C-terminal HA tag
(alpha-synuclein-HA) were grown under standard conditions with
the addition of G418 (0.4 mg/ml) for maintenance of the clone (Chau
et al., 2009). Lysosomal inhibition was achieved by incubating cells
with 20 mM ammonium chloride for up to 7 days, or with 200 nM
baﬁlomycin A1 for up to 72 h. SH-SY5Y cells were differentiated by
treatment with 10 μM all-trans retinoic acid for 7 days.
Cell proliferation
Equal cell numbers of treated and untreated cells were seeded
after various treatments and cell proliferation rates were analysed by
the Celltiter Blue kit (Promega).
Exosome puriﬁcation and cell treatment
Foetal calf serum used for exosome production was centrifuged at
25,000g for 90 minutes at 4 °C before the preparation of medium. Cells
used for exosome isolation were 80–90% conﬂuent, culture medium
was changed 24 h before the isolation of exosomes. Twenty four hour
conditioned medium from 10×10 cm plates of cells (70–80%
conﬂuent) was collected and centrifuged for 10 minutes at 1000g
followed by 12,000g to exclude cell debris, and exosomes pelleted
from the post-12,000g supernatant by centrifugation at 120,000g for
1 h (Quah and O'Neill 2005).
Exosome pellets were resuspended in 100 μl growth medium and
incubated with normal SH-SY5Y cells (70% conﬂuent 35 mmplate) for
16 h.
Exosome immunoprecipitation
Fifty microliters of Protein-A Sepharose beads (Sigma P9424) were
diluted in 500 μl PBS containing BSA (2 mg/ml) and incubated
overnight at 4 °C. The beads were washed 3 times with PBS and
resuspended in 100 μl anti-ﬂotillin-1 antibody (1/100 dilution in PBS/
BSA 2 mg/ml, rabbit polyclonal, Abcam) or anti-tubulin (1/500
dilution in PBS/BSA 2 mg/ml, rabbit polyclonal, Abcam) and incubated
at 4 °C for 4 h. The beads were washed 3 times with PBS, and puriﬁed
exosomes were added to the beads in 200 μl of PBS and incubated for
3 h at 4 °C. After incubation, the beads were washed 3 times with PBS
and eluted in 0.1% SDS for Western blot analyses.
Alpha-synuclein ELISA analysis
To quantify total alpha-synuclein release by cells 24 h conditioned
medium from 2×10 cm plates was concentrated with Amicon Ultra-
15 Centrifugal Filter Unit (Millipore). The medium was sonicated for
20 minutes (sonicator bath), and total released alpha-synuclein was
assessed using an alpha-synuclein ELISA kit (USCN Life) as per
manufacturer's protocol. Results were normalised to the number of
cells on the original plates.
Extraction of alpha-synuclein
Cell pellets were sequentially extracted in high salt (HS, 50 mmol/
l Tris, 750 mmol/l NaCl, 5 mmol/l EDTA), HS/Triton (1% Triton) and
SDS/urea (8 mol/l of urea, 2% SDS) and insoluble material pellet bycentrifugation at 60,000g as previously described (Waxman and
Giasson 2008).
Electron microscopy and Nanoparticle Tracking Analysis (NTA)
For electron microscopy exosome preparations were incubated
with 4% osmium tetraoxide for 30 minutes at 4 °C, then applied onto a
copper grid and stained with 1% phosphotungstic acid.
NTA was carried out using the Nanosight LM10-HS system
(NanoSight, Amesbury, UK) on exosomes resuspended in PBS at a
concentration of approximately 3 μg of protein/ml and were further
diluted between one and ﬁve hundred-fold for analysis. The system
focuses a laser beam through a suspension of the particles of interest.
These are visualised by light scattering, using a conventional optical
microscope aligned normally to the beam axis which collects light
scattered from every particle in the ﬁeld of view. A 20–60 second
video records all events for further analysis by NTA (Nanoparticle
Tracking Analysis) software. The Brownian motion of each particle is
tracked between frames, ultimately allowing calculation of the size via
application of the Stokes–Einstein equation.
Western blots, immunocytochemistry and antibodies
The NuPAGE gel system (Invitrogen) was used for all protein
separations using 4–12% polyacrylamide gel. Cells were lysed in
10 mM Tris pH 7.4 buffer containing 0.1% SDS, a protease inhibitor
cocktail and DNase (Promega, Southampton UK) and incubated for 1 h
at 37 °C. SDS–PAGE separations, Western blot and ECL detection
protocols have been described previously (Chau et al., 2009).
Primary antibodies used for Westerns were mouse anti-Lamp-1
antibody (Abcam 1/5000), mouse anti-Alix (Abcam 1/500), rabbit
anti-ﬂotillin-1 (Abcam 1/1000), mouse anti-HA (Covance 1/5000),
mouse anti-alpha-synuclein (Zymed 1/1000), rabbit anti-actin
(Abcam 1/5000). Secondary antibodies used were HRP-conjugated
anti-mouse or anti-rabbit (DAKO, Ely, UK).
For immunoﬂuorescence SH-SY5Y cells were seeded on coverslips
and immunostained using the anti-alpha-synuclein antibody (1:200),
anti-HA antibody (1:1000) as previously described (Chau et al., 2009).
Images were taken using an Axiophot ﬂuorescence microscope and
KS400 software (Zeiss, Welwyn Garden City, UK) with standardised
exposure times. Confocal analysis was performed using a Zeiss
confocal microscope (LSM 510 Meta), the sections were ﬁrst
examined using low-magniﬁcation lenses (×10 and ×20) and
photographs were taken at higher magniﬁcations (×63 oil immersion
objective).
Statistics
Statistical analyses of the data were performed using SPSS
program 16.0 by using the non-parametric Kruskal–Wallis test
followed by the Mann–Whitney U test. The data are presented as
means±standard deviations and represents results from at least 3
independent experiments.
Results
Exosomes released by SH-SY5Y cells contained and transferred
alpha-synuclein
Exosomes were isolated from normal andWT alpha-synuclein over-
expressing SH-SY5Y conditioned medium (CM) using an established
ultracentrifugation protocol (Quah and O'Neill 2005). Exosomes
obtained from the ultracentrifuge pellets were examined by electronic
microscopy and by NTA. Both techniques demonstrated that a
homogenous population of exosomal vesicles with a size distribution
peaking at a diameter of 93 and 99 nm for normal and alpha-synuclein
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identiﬁed. Western blot analysis conﬁrmed the presence of the
exosomal proteins, LAMP-1, ﬂotillin-1 and Alix (Simpson et al., 2008)
in exosome preparations from both sets of cells. However, alpha-
synuclein protein was detectable only in exosomes from cells over-
expressing alpha-synuclein-HA (Fig. 1c). This ﬁnding was consistent
with the undetectable levels of endogenous alpha-synuclein protein in
normal SH-SY5Y cells (data not shown). Antibodies against ﬂotillin-1
were used to immunoprecipitate exosomes from CM from alpha-
synuclein over-expressing cells. The immunoprecipitate was positive
for LAMP-1 and alpha-synuclein and the ﬂow through medium was
negative for both proteins (Fig. 1d). Quantitation of alpha-synuclein
levels in conditioned medium and ﬂow through using ELISA analysis
(Fig. 1e) conﬁrmed the majority of the alpha-synuclein was associated
with the exosomes.Fig. 1. Analysis of exosomes released by SH-SY5Y. Characterisation of exosomes isolated from
cells: a, Electron micrograph of phosphotungstic acid-stained exosomes; scale bar=200 nm
(green line) or alpha synuclein expressing (red line) SH-SY5Y cells. c, Western blot analysis o
and HA). d, Conditionedmedium from alpha synuclein expressing cells was immunoprecipita
(15 μg) of the ﬂow through (FT) were loaded and probed with anti-LAMP-1 and anti-alpha-s
after IP with ﬂotillin-1 presented as a percentage of the level in the CM.To investigate whether alpha-synuclein could be transmitted from
one cell to another via exosomes we isolated exosomes from CM from
normal and alpha-synuclein over-expressing SH-SY5Y cells and
incubated them with normal SH-SY5Y cells for 16 h. Only the SH-
SY5Y cells incubated with exosomes isolated from alpha-synuclein
expressing cells showed the presence of detectable alpha-synuclein
on Western blot (Fig. 2a) and immunocytochemical analyses (Fig. 2b
and c).This was detected with both anti-alpha-synuclein and anti-HA
antibodies conﬁrming the transmission from the donor cells (Fig. 2b)
and confocal analysis conﬁrmed its intracellular location (Fig. 2c).
Disruption of exosomes by sonication (Stoeckl et al., 2006) prior to
their incubation with recipient cells prevented the transfer of alpha-
synuclein (Fig. 2d), indicating efﬁcient transfer of alpha-synuclein to
recipient cells required intact exosomes. This transfer was not unique
to dividing cells as we were also able to conﬁrm the exosomalconditionedmedium (CM) from normal and alpha-synuclein over-expressing SH-SY5Y
. b, NTA analysis of particle diameters in exosome preparations from CM from normal
f exosomemarkers (LAMP-1, Alix and ﬂotillin-1) and alpha-synuclein (alpha-synuclein
ted (IP) with anti-tubulin or anti-ﬂotillin-1 antibodies. All the eluted IP protein and 40%
ynuclein antibodies. e, ELISA quantitation of alpha-synuclein levels in the ﬂow through
Fig. 2. Analysis of the inter-cellular transfer of alpha synuclein by exosomes, a. Western blot analysis of alpha-synuclein levels (using anti-alpha-synuclein and HA antibodies)
relative to actin in normal SH-SY5Y cells following overnight treatment with exosomes isolated from CM from normal and alpha-synuclein over-expressing SH-SY5Y cells.
b, Immunoﬂuoresence staining for alpha-synuclein (i and ii, anti-alpha-synuclein antibody; iii and iv, anti-HA antibody, arrows) in normal SH-SY5Y cells (i and iii) and after 16 h
exposure to exosomes isolated from CM from alpha-synuclein over-expressing cells (ii and iv). c, Serial confocal Z-projection images (4 μm) of normal SH-SY5Y cells 16 h after
incubation with exosomes isolated from WT alpha-synuclein over-expressing cells, anti-alpha-synuclein antibody (green) and DAPI (blue). d. Western blot analysis of alpha-
synuclein levels (alpha-synuclein antibody) relative to actin in normal SH-SY5Y cells following overnight treatment with intact and sonicated exosomes isolated from CM from
alpha-synuclein over-expressing SH-SY5Y cells. e. Immunoﬂuoresence staining of alpha-synuclein (alpha-synuclein antibody, green) relative to DAPI (blue) in differentiated normal
SH-SY5Y cells grown under control conditions (i) or 16 h after treatment with exosomes isolated from CM from alpha-synuclein over-expressing cells (ii).
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(Fig. 2e).
Inﬂuence of lysosomal inhibition upon alpha-synuclein levels
Alpha-synuclein protein is degraded predominantly through lyso-
somal pathways therefore requiring intact lysosomal function
(Paxinou et al., 2001). In an attempt to mimic the abnormal lysosomal
function described in PD (Alvarez-Erviti et al., 2010) we inhibited
lysosomal function in normal and WT alpha-synuclein over-expressing
SH-SY5Y cells with ammonium chloride for 7 days or with the vacuolar
H+ATPase inhibitor baﬁlomycin A1 for 24 and 72 h (Martinez-Vicente
et al., 2008). There were no adverse effects on cell survival with the
exception of prolonged baﬁlomycin treatment which caused marked
cell loss (Fig. 3a). The level of the autophagosomal marker LC3-II was
increasedwith these treatments consistentwith decreased degradation
of autophagic vacuoles associated with lysosomal dysfunction (Fig. 3band c). Relative to untreated cells alpha-synuclein levels (corrected to
actin levels) increased signiﬁcantly following ammonium chloride
(increased 79.6%±6.3) and baﬁlomycin (increased 71.3%±3.8 after
24 h, 107.5%±11.2 after 72 h) treatment in over-expressing cells
(Fig. 3b–d) but remained undetectable in normal cells (data not
shown). The impact of these treatments upon aggregate formation
was investigated using the differential solubility of alpha-synuclein.
Cellswere sequentially extracted inhigh salt, 1% triton andSDS/ureaand
the relative levelsof alpha-synuclein assessed in each fraction.While the
majority of alpha-synuclein was extracted in high salt medium in all
conditions therewas clearly evidence of a triton insoluble pool of alpha-
synuclein following both ammonium chloride and baﬁlomycin treat-
ments that was not seen in the controls (Fig. 3e). This suggested that
lysosomal dysfunction led to evidence of insoluble alpha-synuclein
consistent with the presence of aggregates; however, while the
immunocytochemical images were consistent with alpha-synuclein
accumulation there was no clear evidence of aggregates.
Fig. 3. Inﬂuence of lysosomal inhibition on alpha-synuclein levels. Analysis of alpha-synuclein overexpressing cells under normal conditions (control) or after treatment with
ammonium chloride or baﬁlomycin A1. a, Inﬂuence of ammonium chloride (20 mM) treatment for 7 days and baﬁlomycin A1 (200 nM) treatment for 24 and 72 h upon cell
proliferation as determined by the Celltiter Blue kit in alpha synuclein over-expressing SH-SY5Y cells. Statistical analysis compared to controls *pb0.05. b and c,Western Blot analysis
of alpha-synuclein (alpha-synuclein antibody) and LC3-I and II levels relative to actin after 7 days ammonium chloride or 24 and 72 h baﬁlomycin A1 treatment. Statistical analysis
compared to controls *pb0.05, **pb0.01. d, Immunoﬂuoresence staining for alpha-synuclein (anti-HA antibody, green) after 7 days of treatment with ammonium chloride or 24 h of
treatment with baﬁlomycin A1. e, Western Blot analysis of alpha-synuclein levels in SH-SY5Y cells treated with ammonium chloride or baﬁlomycin A1. Cells were sequential
extracted with high salt (HS), HS/Triton (Triton) and SDS/urea (urea), and 3%, 3% and 20% of each extract respectively were separated and detected with an anti-alpha-synuclein
antibody.
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Lysosomal dysfunction caused a dramatic increase in total alpha-
synuclein release into the cell medium (increased 300–620% at all
time points assessed, Fig. 4a). The isolation of exosomes from the
conditioned medium demonstrated this marked increase in alpha-
synuclein levels was also apparent in the exosomes after exposure to
ammonium chloride for 7 days (435%±29.8) or baﬁlomycin A1 for
24 h (397.5%±18.2) or 72 h (451.9%±21.6) (Fig. 4b and c).
Following incubation of the exosomes released from alpha-
synuclein over-expressing cells inhibited by ammonium chloridewith normal SH-SY5Y cells, the level of alpha-synuclein present in the
recipient cells was markedly increased compared with that seen in
experiments performed without lysosomal inhibition (increased
307.1±34.1 %, Fig. 4d and e). This was also evident upon
immunoﬂuorescent analysis with an increase in both the intensity
of alpha-synuclein staining (Fig. 4f) and number of recipient cells
containing detectable levels of alpha-synuclein (96% and 38% of
recipients cells after incubation with exosomes from ammonium
chloride treated and untreated cells, respectively). Confocal micros-
copy analysis conﬁrmed the presence of alpha-synuclein throughout
the cell consistent with an intracellular location (Fig. 4g). Moreover,
Fig. 4. Inﬂuence of lysosomal inhibition upon exosome-mediated alpha-synuclein transmission to normal cells. a, ELISA quantitation of total alpha-synuclein release under control
conditions or after ammonium chloride or baﬁlomycin A1 treatment. Data compared to controls, *pb0.05, **pb0.01. b and c, Western Blot analysis of exosomes isolated from CM
from normal and alpha-synuclein over expressing cells grown under control conditions or after ammonium chloride (20 mM for 7 days) or baﬁlomycin A1 (200 nM) treatment.
Alpha-synuclein levels (alpha-synuclein antibody) were evaluated relative to an exosome marker, Flotillin-1. Statistical analysis compared to controls **pb0.01. d and e, Western
Blot analysis of alpha-synuclein levels (alpha-synuclein antibody) relative to actin in normal SH-SY5Y cells following 16 h incubation with exosomes isolated from CM from normal
and alpha-synuclein over-expressing SH-SY5Y cells grown in the absence or presence of ammonium chloride (7 days). Statistical analysis compared to controls **pb0.01.
f, Immunoﬂuoresence staining of alpha-synuclein (alpha-synuclein antibody) in (i) normal untreated SH-SY5Y cells, and (ii) normal SH-SY5Y cells after 16 h incubation with
exosomes isolated from alpha-synuclein over-expressing cells, (iii–v) alpha-synuclein over-expressing cells after ammonium chloride treatment, (iv and v) demonstrating peri-
nuclear alpha-synuclein accumulation (arrows). All studies were with dividing SH-SY5Y cells except for panel v where the recipient cells had been differentiated for 7 days. g, Serial
confocal Z-projections of normal SH-SY5Y cells 16 h after incubation with exosomes isolated fromWT alpha-synuclein over-expressing cells treated with ammonium chloride, anti-
alpha-synuclein antibody (green) and DAPI (blue).
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cells after incubation with exosomes from untreated cells) was also
more apparent in cells incubated with exosomes from ammonium
chloride treated cells (seen in 3.6% of cells) (Fig. 4f, panels iii and iv).
These observations were not only restricted to the transfer of alpha-
synuclein to mitotic cells as similar results were obtained when
exosomes were incubated with differentiated SH-SY5Y cells (Fig. 4f,
panel v).
Discussion
While there is clear evidence that alpha-synuclein plays an
important role in PD pathology, its exact role in pathogenesis remains
unclear. Alpha-synuclein is prone to aggregation leading to its
presence in LB; however, the debate as to whether soluble protoﬁbrils
or aggregates of alpha-synuclein are the pathological entity remains
to be resolved. The Braak staging of PD pathology suggests that there
is a progression of LB pathology from the brainstem to the cortex
consistent with pathological propagation along speciﬁc neural path-
ways (Braak et al., 2003). The recent ﬁnding of Lewy body inclusions
in embryonic dopaminergic nerve cells implanted into the striatum
of patients with PD (Li et al., 2008; Kordower et al., 2008) has given
fresh impetus to the importance of alpha-synuclein propagation in PD
pathology.
While alpha-synuclein is predominantly a cytosolic protein
associated with dopamine metabolism, extracellular alpha-synuclein
has been observed in CSF and plasma in humans (Borghi et al., 2000;
El-Agnaf et al., 2003). The release of alpha-synuclein from cells via
exocytosis has been previously reported in SH-SY5Y cells over-
expressing human alpha-synuclein (Lee et al., 2005) and associated
with membrane vesicles whose identity is compatible with exosomes
(Emmanoulidou et al., 2010), and we have conﬁrmed this observa-
tion. The possibility of pathological alpha-synuclein propagation
between cells was further strengthened when alpha-synuclein was
recently shown to be transferred to neighbouring cells, via a process
involving endocytosis (Desplats et al., 2009). However to date the
precise mechanisms of alpha-synuclein release and uptake by
recipient cells remains ill deﬁned.
Exosomes have been previously associatedwith pathological prion
protein transmission from neuronal and non-neuronal infected cell
lines to uninfected recipient cells (Fevrier et al., 2004; Alais et al.,
2008). We have demonstrated that alpha-synuclein released from SH-
SY5Y cells can be recovered by a centrifugation protocol used to purify
exosomes (Quah and O'Neill 2005). While exosomes do not have any
unique characteristic feature, a combination of features is accepted as
evidence of their identity (Simpson et al., 2008). The characterisation
of vesicle preparations in this study revealed an electron microscopic
appearance, vesicle size proﬁle and the presence of LAMP-1, ﬂotillin-1
and Alix proteins, all of which are indicative of an exosomal identity.
These results are in agreement with observations from cells with
inducible expression of alpha-synuclein (Emmanoulidou et al., 2010).
We were also able to immunoprecipitate the exosomes from alpha-
synuclein over-expressing cells which pulled down the majority of
the alpha-synuclein in the medium consistent with the role of
exosomes in the extracellular release of alpha-synuclein. The isolated
exosomes were capable of transferring alpha-synuclein to naive cells;
however, sonicated exosomes were no longer able to efﬁciently do
this outlining the importance of the exosome in this transfer
mechanism. This transfer was not restricted to dividing cells as
similar data were obtainedwith differentiated SH-SY5Y recipient cells
demonstrating the exosome mediated transfer of alpha-synuclein
could be effective in differentiated neurones. Confocal microscopy
analysis was consistent with the intracellular localisation of alpha-
synuclein within the recipient cells. While not all cells stained positive
for the transferred alpha-synuclein, occasional cells showed the
presence of large inclusions. These could represent vesicle boundalpha-synuclein or the presence of aggregates but were not abundant
enough for deﬁnitive analysis.
While it is apparent that alpha-synuclein is transferred between
cells, its relevance to normal physiology or pathology is not clear.
Equally, while the transmission of alpha-synuclein could lead to the
propagation of this protein throughout the brain, its transfer between
cells may not be sufﬁcient in itself to transmit the pathology
associated with PD. It is therefore important to demonstrate that
this process can be involved in the propagation of aggregated alpha-
synuclein in a manner similar to that suggested for prion diseases
(Fevrier et al., 2004; Alais et al., 2008). It is possible that the transfer of
alpha-synuclein from one cell to the next initiates a cell stress
response ultimately leading to alpha-synuclein aggregation and
further transmission to neighbouring cells (Desplats et al., 2009).
Equally the biochemical abnormalities found in PD brains could
exacerbate the propagation of a pathological form of alpha-synuclein
which, when transferred to neighbouring cells, acts to ‘seed’ aggregate
formation.
In an attempt to model the generation of an aggregate prone form
of alpha-synuclein we investigated the effect of lysosomal inhibition.
Lysosomal function has been reported to be decreased in PD patients
(Chu et al., 2009; Alvarez-Erviti et al., 2010) and alpha-synuclein is
known to require the lysosome for its degradation (Paxinou et al.,
2001). In an attempt to mimic a defect of intracellular protein
handling in PD we inhibited lysosomal function in the exosome donor
cells using ammonium chloride or baﬁlomycin A1. Lysosomal
inhibition by ammonium chloride for 3 and 7 days and baﬁlomycin
for 24 h and 72 h all dramatically increased alpha-synuclein release
from the SH-SY5Y cells. However, this was only associated with
signiﬁcant cell death in cells treated with baﬁlomycin for 72 h
consistent with exosome mediated alpha-synuclein release and not
a consequence of cell death. While lysosomal inhibition increased the
cellular content of alpha-synuclein, we were unable to detect any
clear evidence of intra-cellular protein aggregates; however, there
was an increase in triton insoluble alpha-synuclein suggesting the
presence of aggregates. The increase in cellular alpha-synuclein levels
was associated with a dramatic increase in exosomal alpha-synuclein
release which led to greater transmission of alpha-synuclein to
recipient cells and a greater number of cells containing alpha-
synuclein inclusions. These data suggest that the increased exosomal
release of alpha-synuclein may be inﬂuenced by the increase in
intracellular alpha-synuclein consistent with the suggestion that in
neurons exosomes may play a direct role in the removal of unwanted
proteins (Putz et al., 2008).
We hypothesise that changes to lysosomal function in PD can
accelerate exosomal alpha-synuclein release and propagation to
neighbouring cells and a concomitant increase in alpha-synuclein
inclusion formation. We believe that this cellular model is a useful
approach to test whether other biochemical changes observed in PD
can lead to the generation of pathological forms of alpha-synuclein in
donor cells that can be propagated via exosomes to other cells and
play a role in PD pathogenesis.
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